Trial Profile

Randomized, multicenter study comparing the immediate adjuvant radiotherapy associate with hormonal therapy of LH-RH analogue (Decapeptyl LP) vs delayed radiotherapy until biochemical relapse associated with hormonal therapy of LH-RH analogue (Decapeptyl LP) in patients with operable prostate cancer pT3 R1 pN0 or pNx at intermediate risk.

Status: Discontinued

Phase of Trial: Phase III

Latest Information Update: 23 Feb 2022

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

01 Oct 2020 Primary endpoint has not been met. (Event-free survival (clinical progression, biochemical progression, death) at 5 years)
01 Oct 2020 Status changed from active, no longer recruiting to discontinued.
01 Oct 2020 Results published in the Lancet Oncology

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com